Data from our in vivo studies demonstrated that IL-1β is robustly induced during GAS skin infection in both an SLS-dependent and independent manner, and that inhibition of this inflammatory cascade leads to reduced skin lesion formation early in the infection process. The gene discussed is IL1B; the disease is flatulence.